Cassava Sciences, Inc. (SAVA) Stock Analysis & Investment Frameworks
Cassava Sciences, Inc. (SAVA) stock analysis on Invetso. Review Cassava Sciences, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Cassava Sciences, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Cassava Sciences, Inc. Key Financial Metrics
- Market Cap: $63.77M
- Revenue: $N/A
- ROE: -58.78%
- ROIC: -70.87%
- Dividend Yield: N/A
About Cassava Sciences, Inc.
Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.